posted on 2022-06-28, 17:33authored byTimo Heinrich, Carl Peterson, Richard Schneider, Sakshi Garg, Daniel Schwarz, Jakub Gunera, Anita Seshire, Lisa Kötzner, Sarah Schlesiger, Djordje Musil, Heike Schilke, Benjamin Doerfel, Patrizia Diehl, Pia Böpple, Ana R. Lemos, Pedro M. F. Sousa, Filipe Freire, Tiago M. Bandeiras, Emma Carswell, Nicholas Pearson, Sameer Sirohi, Mollie Hooker, Elisabeth Trivier, Rebecca Broome, Alexander Balsiger, Abigail Crowden, Christian Dillon, Dirk Wienke
The dysregulated Hippo pathway and,
consequently, hyperactivity
of the transcriptional YAP/TAZ-TEAD complexes is associated with diseases
such as cancer. Prevention of YAP/TAZ-TEAD triggered gene transcription
is an attractive strategy for therapeutic intervention. The deeply
buried and conserved lipidation pocket (P-site) of the TEAD transcription
factors is druggable. The discovery and optimization of a P-site binding
fragment (1) are described. Utilizing structure-based
design, enhancement in target potency was engineered into the hit,
capitalizing on the established X-ray structure of TEAD1. The efforts
culminated in the optimized in vivo tool MSC-4106, which
exhibited desirable potency, mouse pharmacokinetic properties, and
in vivo efficacy. In close correlation to compound exposure, the time-
and dose-dependent downregulation of a proximal biomarker could be
shown.